These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 8590851

  • 1. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
    Okabe M, Maekawa I, Suzuki S, Higuchi M, Morioka M, Nishi K, Itaya T, Ohmura T, Kawamura M, Fuzimoto N.
    Leuk Lymphoma; 1995 Nov; 19(5-6):485-91. PubMed ID: 8590851
    [Abstract] [Full Text] [Related]

  • 2. Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
    Kuni-Eda Y, Okabe M, Kurosawa M, Maekawa I, Higuchi M, Kawamura M, Morioka M, Suzuki S, Ohmura T, Fujimoto N.
    Leuk Lymphoma; 1995 Feb; 16(5-6):471-6. PubMed ID: 7540462
    [Abstract] [Full Text] [Related]

  • 3. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    N Engl J Med; 1993 Apr 08; 328(14):1002-6. PubMed ID: 7680764
    [Abstract] [Full Text] [Related]

  • 4. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M, Li L, Qiu M, Yan X, Zhu J, Gou HF.
    Ai Zheng; 2005 Apr 08; 24(4):461-4. PubMed ID: 15820070
    [Abstract] [Full Text] [Related]

  • 5. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP.
    Ann Oncol; 1994 Apr 08; 5 Suppl 2():91-5. PubMed ID: 7515652
    [Abstract] [Full Text] [Related]

  • 6. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Rossi G, Donisi A, Casari S, Re A, Stellini R, Cadeo G, Carosi G.
    Haematologica; 1998 Apr 08; 83(4):317-22. PubMed ID: 9592981
    [Abstract] [Full Text] [Related]

  • 7. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 08; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Mar 08; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI, Longo DL, DeVita VT, Hubbard SM, Miller TP, Young RC.
    Ann Oncol; 1991 Jan 08; 2 Suppl 1():33-5. PubMed ID: 1710487
    [Abstract] [Full Text] [Related]

  • 10. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI.
    J Clin Oncol; 1991 Jan 08; 9(1):25-38. PubMed ID: 1702144
    [Abstract] [Full Text] [Related]

  • 11. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL, Duffey PL, Jaffe ES, Raffeld M, Hubbard SM, Fisher RI, Wittes RE, DeVita VT, Young RC.
    J Clin Oncol; 1994 Oct 08; 12(10):2153-9. PubMed ID: 7523607
    [Abstract] [Full Text] [Related]

  • 12. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI.
    J Clin Oncol; 1990 Dec 08; 8(12):1951-8. PubMed ID: 1700079
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P.
    J Clin Oncol; 1996 Apr 08; 14(4):1275-81. PubMed ID: 8648384
    [Abstract] [Full Text] [Related]

  • 14. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
    Montserrat E, García-Conde J, Viñolas N, López-Guillermo A, Hernández-Nieto L, Zubizarreta A, Maldonado J, Alcalá A, Faura MV, Llorente A, Bladé J, Fontanillas M, Estapé J.
    Eur J Haematol; 1996 Nov 08; 57(5):377-83. PubMed ID: 9003479
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 08; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 16. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A, Salvagno L, Coser P, Porcellini A, Vespignani M.
    J Clin Oncol; 1994 Jul 08; 12(7):1366-74. PubMed ID: 7517442
    [Abstract] [Full Text] [Related]

  • 17. [Different chemotherapy protocols for intermediate and high grade malignant non-Hodgkin's lymphoma].
    Wang A, Luo Y, Wang Z.
    Zhonghua Zhong Liu Za Zhi; 1997 May 08; 19(3):215-7. PubMed ID: 10920901
    [Abstract] [Full Text] [Related]

  • 18. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
    Cassi E, Butti C, Baldini L, Pisoni GB, Ceriani A, Confalonieri C, Scandolaro L, De Paoli A, Lombardi F, Montalbetti L.
    Leuk Lymphoma; 1994 Mar 08; 13(1-2):111-8. PubMed ID: 7517742
    [Abstract] [Full Text] [Related]

  • 19. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma.
    Armitage JO.
    Ann Oncol; 1991 Jan 08; 2 Suppl 1():37-41. PubMed ID: 1710488
    [Abstract] [Full Text] [Related]

  • 20. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
    Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M.
    Int J Oncol; 2000 Jan 08; 16(1):149-54. PubMed ID: 10601560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.